<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209661</url>
  </required_header>
  <id_info>
    <org_study_id>2016-04-0115</org_study_id>
    <nct_id>NCT03209661</nct_id>
  </id_info>
  <brief_title>Vascular Effects of a Single Bout of Electronic Cigarette Use</brief_title>
  <official_title>Vascular Effects of a Single Bout of Electronic Cigarette Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the acute effects of a single use E-Cigarette upon vascular health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will inhale e-cigarettes of 5.4%, 0%, and sham menthol inhaler to determine the
      effects upon to measures of vascular health. These measures will include Cardio-Ankle
      Vascular Index and Flow Mediated Dilation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be asked to inhale one of three mediums; 5.4% NBV e-ciggarette, 0% NBV cigarette, and sham menthol inhaler (no vapor). Baseline measurements will be conducted upon arrival and followed immediately post inhalation, 1-hour post, and finally 2-hours post. All trials will require a minimum of 48 hours washout.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>E-cigarettes being utilized are of the same brand and design. Additionally, the device will be covered by a sheath to ensure labeling is not visible to the subject.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in arterial stiffness and endothelial function with e-cigarette use.</measure>
    <time_frame>Immediately Post, 1 hour, and 2 hour.</time_frame>
    <description>Arterial stiffness and endothelial function are two of the subclinical markers of vascular dysfunction</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Arterial Stiffness</condition>
  <arm_group>
    <arm_group_label>E-Cigarette 5.4% NBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be asked to inhale an E-Cigarette with 5.4% NBV for 6 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-Cigarette 0% NBV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be asked to inhale an E-Cigarette with 0% NBV for 6 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menthol Inhaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be asked to inhale a sham methole inhaler (that looks identical in looks to E-cigarette) for 6 minutes. This arm is to control for a potential effect of menthole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E-cigarette</intervention_name>
    <description>E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.</description>
    <arm_group_label>E-Cigarette 5.4% NBV</arm_group_label>
    <other_name>Nicotine 5.4%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine 0%</intervention_name>
    <description>E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.</description>
    <arm_group_label>E-Cigarette 0% NBV</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Menthol Inhalant Product</intervention_name>
    <description>Menthol inhaler will be administered to determine the effects on vascular function.</description>
    <arm_group_label>Menthol Inhaler</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Apparently healthy, with no cardiovascular or metabolic diseases. Additionally, is not
             a frequent smoker of any kind.

        Exclusion Criteria:

          -  Cardiovascular or Metabolic Diseases and/or regular smoker.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hirofumi Tanaka, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Aging Research Lab at UT Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vascular function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

